leadf
logo-loader

Small Cap Movers: Drugs giant inks collaboration deal with artificial intelligence-driven diagnostics specialist, RenalytixAI

A look back at some of the more interesting stories from London's junior market this week

Drug testing
Renalytix and AstraZeneca will work on precision medicine strategies for cardiovascular, renal and metabolic diseases

Since March AstraZeneca (LON:AZN) has inked three significant deals with some lesser lights of the drugs sector quoted on the LSE’s alternative investment market.

Remember, the Anglo-Swedish giant, which is now the FTSE 100’s largest company, has one of the industry’s most productive drugs pipelines and is noted for some innovative industry collaborations.

Its interest in AIM started with an out-licensing agreement with Silence Therapeutics (LON:SLN) worth up to £303mln per disease area in commercial development milestones and tiered royalty payments.

This came coupled with an upfront payment and equity investment of £61mln that means the gene silencing specialist won’t have to worry about its bank balance for many years.

RedX Pharma was the next to feel the ‘AZ love’ with a transaction like Silence’s, but worth slightly less at £283mln (plus a £13mln down-payment).

RedX shares are up more than 400% in the year to date at 38p, while Silence has enjoyed a rather more modest 27% uplift in that time to 456p.

Friday saw the drug giant deepen its association with AIM after striking a collaboration with artificial intelligence-driven diagnostics specialist, RenalytixAI (LON:RENX), whose stock shot up 14% to 645p.

The pair will work on precision medicine strategies for cardiovascular, renal and metabolic diseases.

AZ also has longer-standing ties with Hutchison China MediTech (LON:HCM), one of AIM’s largest companies, and Circassia Group (LON:CIR), the asthma management specialist, where it is the largest investor.

Turning to the wider market, the AIM All-Share was more or less flat this week at 956 points, which meant it outperformed significantly the top stocks benchmark, with the FTSE 100 down almost 1.5% in that period.

Sticking with the AIM winners, it was another stellar week for 7Digital (LON:7DIG), which rocketed 180% higher to 3.21p.

So hot has the stock been recently that a £1,000 investment a month ago would be worth £13,600. The springboard for this week’s movement was a music deal with an unnamed tech giant.

Before looking at the week’s losers, worth an honourable mention is HC Slingsby (LON:SLNG), up 79% to 220p after reporting bumper demand for its industrial equipment.

But down 24.5% at 13.9p this week was Europa Metals (LON:EUZ), though this was purely technical after the company raised £2mln of new cash to do something positive – to fund the completion of key components of a pre-feasibility study for its Toral lead-zinc-silver project in Spain.

Europa’s was one of a number of fundraisers on AIM over the week that included share placings by Active Energy (LON:AEG), Equatorial Palm Oil (LON:PAL), Immedia (LON:IME), Eurasia Mining (LON:EUA) and One Media IP (LON:OMIP).

Digital rights specialist One Media’s £6mln funder stood out as it was heavily over-subscribed, suggesting there is still plenty of cash out there for companies with interesting ways in which to deploy those funds.

CEO Michael Infante and his team are investing heavily in Harmony iP, which borrows from the equity release plans that dominate the ad slots on daytime TV.

Rather than acquiring whole music catalogues, Harmony has set itself up buy between 10% and 30% valued on a multiple of the income the music generates. The shares ended the week down 9% at 6.75p.

“The level of demand for the lacing reflects the confidence existing and incoming investors have in One Media’s Harmony iP model and the ongoing strategy to capitalise on a market benefiting from significant tailwinds,” said Infante.

Eurasia’s institutional cash call was another that garnered a great deal of interest – so much so the miner was able to raise £7.6mln without having to discount the price of the new shares.

The funds will be used to ramp up production of palladium, platinum, rhodium, iridium and gold at the Urals mine it owns in the Urals region of Russia.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Amryt Pharma presents at the Proactive One2One virtual conference

Amryt Pharma's LON:AMYT) Rory Nealon presents at the Proactive One2One virtual conference. Amryt Pharma is a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of people with rare and orphan diseases. The company...

1 day, 11 hours ago

4 min read